Company hopes to make antenatal infectious disease and thrombophilia panels available this year.
Enzo Biochem negotiated exclusive rights to market MultiGEN Diagnostics’ multiplex DNA sequencing-based products in the state of New York. The deal also gives Enzo nonexclusive marketing rights for other regions of the U.S.
Enzo plans to validate and seek approval of MultiGEN’s antenatal infectious disease and thrombophilia panels, which comply with New York, New Jersey, and CLIA requirements. The firm says that it hopes to make the tests available during the latter half of 2010.
The antenatal panel allows the simultaneous identification of specific bacterial, viral, or fungal pathogens using a single specimen. The thrombophilia panel detects mutations indicative of genetic predisposition to blood clotting.
MultiGEN claims Enzo is ideally placed to offer the tests in its designated regions. “MultiGEN has developed a truly novel next-generation multiplex sequencing technology that advances the accuracy and utility of these diagnostic tests,” remarks T. Vinayagamoorthy, Ph.D., MultiGEN president and founder. “Enzo Clinical Labs’ innovative capabilities in developing tests in New York State, combined with their existing commitment to offer world-class diagnostics in the women’s health arena make them the perfect partner for us.”
Enzo believes that the tests will boost its portfolio of women’s health diagnostics. “These particular tests utilize true state-of-the-art technology and offer physicians serving women highly accurate and convenient options for improved patient services,” states Kevin Krenitsky, M.D., president of Enzo Labs.
